"Eagle Clinical Research is a clinical research company based in Chicago, IL. Our mission is to promote wellness and contribute to improving health care through integrated clinical research, education, and discovery."

During the past decade, Eagle Clinical Research conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Eagle Clinical Research" are "COVID-19" (1 trials), "Chlamydia" (1 trials), "Crohn's Disease" (1 trials), "Gonorrhea" (1 trials) and "Hypertension" (1 trials). Many other conditions were trialed in "Eagle Clinical Research" in a lesser frequency.

Most popular intervention types in "Eagle Clinical Research" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "EVO100" (1 trials), "IONIS-AGT-LRx" (1 trials), "Mirikizumab" (1 trials) and "PBI-0451 (Pomotrelvir)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Eagle Clinical Research" are 3 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Eagle Clinical Research". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Eagle Clinical Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Eagle Clinical Research, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".